Energy Industry News
Home | Energy News | Submit Press Release | About Us


Free Utility & Energy Magazines
Press release distribution service

Energy Media
AltEnergyMag
Clean Energy Report
Colorado Energy News
Energy: MIT Tecnology Review
Energy Business Review
Energy Cities
EUROPA
Fuel Fix
Financial Times
Interfax Energy
Green Energy Times
News York Times
NBC News
NPR
Oil & Gas Investor
Oil Price
Platt
PennEnergy
Reuters
RechargeNews
Resilience
Science Daily
Renewable Energy World
Renewable Energy Transportation
The Daily Energy Report
The Energy Daily

Energy Industry News Releases

VFC's Stock House Weekly Stock Watch, Week of 1 October

(EnergyIndustry.Net, October 01, 2012 ) New York, NY -- A new quarter kicks off with a bang this week as new jobs and manufacturing data are slated for release while the US Federal Reserve Chairman Ben Bernanke will issue new comments relating to the economy on Monday. It's also expected that Spain will officially request a bailout this week and the first of three US Presidential debates will take place on Wednesday, positioning the coming week as one that could be filled with high trading volume, excitement and volatility.



At the conclusion of each week, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well.



The following individual stock write-ups are abbreviated reports, with the full discussion available by visiting: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-1-october-rimm-goog-aapl-fb-cpst-fcel-dndn-ino-sgyp-irwd-frx-aezs-onty-oncs



Trading patterns have remained relatively sideways over the past couple of weeks as the markets remain the range of their multi-year highs and any earnings or economic surprises could, in theory, spark a further move higher while any worse-than-expected numbers would likely provide the downward pressure that many media outlets were predicting would materialize over the past few weeks.



Earnings season will also be 'full steam ahead' this week, with investors noting the already-modest expectations, but also keeping a keen eye on any surprises that might justify another bullish move.



As always, the wild card is geo-politics. Aside from our own election season in the US, citizen protests have stormed through Europe all weekend, threatening to apply additional unwanted pressure to newly-elected governments in the region. Continued instability in the Middle East also threatens to play a role in the markets, but such threats have been held at bay since early this year, offering investors secure reason for optimism. It's always wise to entertain all sides of a story, however, and that includes exploring the possibilities of interference from these external factors. Internally, too, many in the media are wondering aloud whether the current economic climate can support the markets sustaining their recent highs - and it's a valid question. If the economic data is hardly improving, then it's hardly believable that there is more upside potential left than down, so this quarter may necessitate some extra investor alertness.



Barely a month now before the US elections will be done and over with, so at least all the related nonsense and fact-manipulating on TV and Facebook can be put to rest and the political hostility can die down, but in the meantime the NFL got their real refs back, so here's to at least having a couple of evenings during the week to escape the madness.



As the last quarter of 2012 gains momentum this week, there's sure to be a few hot stocks and stories to watch - here's just a few of them...



Internet/Technology:



Research In Motion (RIMM): Shares of Research in Motion, the maker of BlackBerry smartphones, opened last week at $6.37 as investors and analysts continued to predict a pessimistic outlook for the one-time tech giant, but a surprisingly optimistic fiscal second quarter earnings report from the company sent shares flying higher on Friday, with RIMM once again surpassing the eight dollar mark before profit taking dropped the stock to a $7.50 close. Volume was over five times the daily average and many wondered if this was the turning point that the company has so desperately needed before falling hard from its perch as a dynamic leader in smartphone technology.



Most encouraging from the latest report was the quarter-over-quarter two percent growth in revenue (from $2.8 to $2.9 billion) and the corresponding growth in cash, cash equivalents and investments, which increased to $2.3 billion - from $2.2 billion - by the end of the quarter. The BlackBerry subscriber base was also up to eighty million globally. All things considered, this report could be a sign that the worst is behind RIM and the company could now be well positioned to capitalize on the launch of the BlackBerry 10 platform, scheduled for early 2013.



Facebook Inc. (FB): Facebook shares took a beating during the late-summer months, dropping to lows of under eighteen dollars as the first major round of selling occurred following the expiration of a key lock-up period in mid-August. Even following the August expiration about 243 million additional shares will become available for trading over the next couple of months as more lock-up periods come to and end, but November 14th could be the D-Day as a whopping 1.2 billion shares are slated to enter the market on that day, according to a Reuters report from late August. The lock-up periods are a sort of 'controlled release' of shareholder shares that forbid shareholders participating the IPO from selling until a specified time. Given that the IPO was priced at $38 dollars and investors started fleeing at the first sign of trouble, the FB dip could have been much more protracted had the lock-ups not been in effect, but it's definately a concern now as the expirations have thus far led to additional share price drops.



Industry, Clean Energy, Green Technology:



Capstone Turbine (CPST): Capstone Turbine shares closed last week at the dollar mark, right at the price around which the stock has been hovering for the better part of the summer. Historically, CPST has proven time and again to at least turn into a decent trade with purchases of at or below a buck, but as long as investors continue to wait impatiently for profitability to come, CPST may continue to be treated as more of a trade than as a long term hold - although there could be merit to both strategies.



FuelCell Energy (FCEL): FuelCell Energy is another clean energy company that has fallen upon hard times - in terms of a share price drop - over the past couple of quarters and currently trades for below ninety cents, well below its 52-week high. FuelCell develops and produces fuel cells for commercial, industrial, government and utility customers and has multiple international deals in place that position the company to capitalize on the growing trend towards clean energy.



Healthcare, Biotech, Pharmaceutical:



Dendreon (DNDN): With a near-four percent share price rise on Friday and a key announcement of expanded coverage for the company's immontherapeutic prostate cancer treatment, Provenge, Dendreon may be looking to make a rebound. Shares crashed last summer when it became painfully apparent that the expensive treatment was not catching on as quickly as investors had hoped and have since remained at the five dollar mark or below, barring the occasional speculative move higher. The expanded Provenge coverage came from Aetna (AET) and provided a spark of hope for investors still looking for this one-time high-flyer to rebound. Aetna, the third-largest health insurer in the United States, had previously allowed coverage of Provenge under more stricter conditions than the revamped guidelines.



Inovio Pharmaceuticals (INO): Shares of Inovio Pharmaceuticals again slipped to below the sixty cent mark on Friday, but with nine programs in development - and three of those in Phase II - it could be worth keeping this company on the radar. Through its proprietary SynCon vaccine design process, Inovio has developed a full pipeline of synthetic vaccines that are designed to universally treat multiple and emerging strains of a virus - instead of just targeting a single strain for treatment, as is the case with today's vaccine development. For example, rather just focusing on fighting one strain of the influenza virus, Inovio has concentrated on developing a 'universal' flu shot. Interim results of early trials to this effect have been encouraging thus far, as data showed that the universal H1N1 influenza vaccine proved effective against some of the most prevalent strains of H1N1 from the past 100 years. Inovio has also reported positive results in a similar H5N1 trial - among others - which offers multiple early validations of the technology in the clinical environment. Although still early in development, a universal flu vaccine hits home to the average citizen - and investor - which could be a good reason why INO receives a nice price and volume spike anytime its universal flu vaccine reaches a definitive milestone.



Full discussion regarding Inovio available by visiting: http://vfcsstockhouse.com/blog/article/-inovio-pharmaceuticals-oncosec-medical-and-the-evolution-of-electroporation



Synergy Pharmaceuticals (SGYP): Still a key stock to watch moving into the final quarter of the year based on a pending Plecanatide trial catalyst later this year that could spark a rally to better align the potential of Synergy's pipeline to that of Ironwood Pharmaceuticals' (IRWD), SGYP received another boost last week as Cantor Fitzgerald initiated coverage on the company with a rating of 'Buy.' Shares pushed towards the five dollar mark on the news, but closed the week modestly lower at $4.78. The Cantor analyst compared Plecanatide's market potential as somewhat less than that of Ironwood's Linzess, which is partnered with Forest Laboratories (FRX) and was approved by the FDA one month ago, but also noted that the company could become an immediate takeover candidate if the results from the Plecanatide trials look good later this year.



Synergy Pharmaceuticals positioning for pipeline payoff: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-positioning-for-pipeline-payoff



AEterna Zentaris (AEZS): AEterna shares had quite the volatile week last week, dropping rather significantly on news that the FDA would not allow a rolling review of their NDA for AEZS-130, a diagnostic test for adult growth hormone deficiency. AEZS rebounded swiftly on Friday, however, registering a fourteen percent increase as investors digested the news and likely realized that the FDA decision was a relatively minor factor in the grand scheme of pipeline progression. The ruling does not effect the timing for AEterna's planned AEZS-130 filing, which is still slated for early 2013. It also should not effect the company's chances of receiving a priority review for the product, according to statement made by President and CEO, Dr. Juergen Engel. Before the share price dip following the news AEZS had caught fire when Roth Capital initiated coverage on the company with a rating of 'Buy' and a price target of $1.75. The enthusiastic Roth rating was based mainly on a developing pipeline that is entering the late stages and includes the Phase III Perifisone for multiple myeloma, the aforementioned AEZS-130, and AEZS-108, which has already proven successful in multiple Phase II trials and is being prepared for a Phase III trial in the treatment of endometrial cancer.



For full discussion regarding AEterna visit: http://vfcsstockhouse.com/blog/article/-aeterna-in-the-spotlight-following-bullish-analyst-coverage



Oncothyreon Inc. (ONTY): Oncothyreon shares moved lower last week, but with key late stage results for the ongoing Phase III Stimuvax trials in the treatment of non-small cell lung cancer, this will be one to watch for the coming months. Results from the Stimuvax trial are slated to start rolling out in early 2013 and - as evidenced by Dendreon (DNDN) in its hey-day - shares of companies in the cancer immunotherapy sector reporting positive Phase III results could spike by monumental margins. Those bullish on the prospects of Stimuvax will keep that in mind, while the bears will note the unimpressive success rate in trials proving the effectiveness of immunotherapeutic cancer treatments.



OncoSec Medical Incorporated (ONCS): Trading volume for OncoSec Medical tailed off late last week, although the company has continued to make steady progress in the advancement of its non-surgical pipeline of cancer-fighting technology. Using electroporation technology, which uses electrical pulses to more accurately and efficiently deliver anti-cancer treatments into cancerous cells without damaging surrounding tissue, the company has devised the OncoSec Medical System (OMS). From that platform ONCS has created two technological pipeline paths, ImmunoPulse and NeoPulse. ImmunoPulse uses the electroporation process to spark a patient's immune system to target cancerous cells itself while NeoPulse uses the OMS technology to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.



Full discussion regarding OncoSec available by visiting: http://vfcsstockhouse.com/blog/article/-oncosec-medical-one-to-keep-an-eye-on-given-recent-developments-and-pipeline-potential



Roundup: Eyes will be on earnings, financial data, politics and developments in the Middle East/North Africa region where events continue to unfold at a pace that is becoming increasingly hard to ignore. Europe will again be in the spotlight, as events in Spain could dictate the immediate health of the global recovery just as the Catalan separatist movement gains steam. Volatility has been predicted by many over the past month or so, as September is known to be an historically bad one for the markets, but the multi-year highs stood firm, almost daring a bit of data to challenge their strength. As in investing in individual stocks, it's a wise move, in my opinion, to entertain all possibilities and it's still tough to believe that the market is not holding onto more downside potential than upside right now. After all, we all know how sluggish the recovery has been - and still is. That doesn't mean, however, that we can't have some fun of our own looking for the steals and deals of the market as the MLB post season kicks off and the French paparazzi follow Kate Middleton around with those long range lenses trying to make the cash in their own kinda creepy way.



Happy Trading!!!



Disclosure: Long SGYP, FCEL, CPST.



Follow developments of these and other small cap stockst at VFCsStockHouse.com



Contact VFC's Stock House: vfc@vfcsstockhouse.com



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com: VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com













VFC's Stock House

VFC

240-786-2111

vfc@vfcsstockhouse.com

Source: EmailWire.Com

Renewable Energy News




Press release service Free Utility & Energy Magazines
Press release distribution service
:: Home: :: Submit Press Release :: Subscribe to News :: Contact Us :: Help

For unlimited press release distribution for $59 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com.

Copyright 2008 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
EnergyIndustry.Net is a Energy news service of GroupWeb Media LLC